Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts; Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut; Chair, ACR RFS Women and Diversity Advisory Group; and Past-Past President, RFS of Radiological Society of Connecticut. Electronic address: https://twitter.com/fsodagari.
Service Chief and Vice Chair in Department of Radiology, Michigan Medicine, Ann Arbor, Michigan; Vice Chair of the Commission on Quality and Safety for ACR; and Board of Directors for Society of Advanced Body Imaging. Electronic address: https://twitter.com/MattDavenportMD.
J Am Coll Radiol. 2024 May;21(5):795-804. doi: 10.1016/j.jacr.2023.04.024. Epub 2023 Jul 27.
To determine whether updated guidance by the ACR in 2017 advocating use of intravenous (IV) premedication in emergency department (ED) patients and inpatients with reported iodinated contrast allergy was associated with a change in clinical practice.
An anonymous survey was distributed via e-mail in October 2020 to practicing radiologist members of the ACR interrogating use of corticosteroid premedication for two clinical vignettes: an indicated routine (perform within 24 hours) inpatient contrast-enhanced CT (CE-CT) and an indicated urgent (perform within 6 hours) ED CE-CT. In both scenarios, the patient had a prior moderate hypersensitivity reaction to iodinated contrast media. Clinical management was evaluated. Data were compared to historical controls from 2009.
The response rate was 11% (724 of 6,616). For the inpatient scenario, 72% (518 of 724) would use corticosteroid premedication with CE-CT, and 28% (200 of 724) would perform noncontrast CT. For the ED scenario, 67% (487 of 724) would use corticosteroid premedication with CE-CT, and 30% (217 of 724) would perform noncontrast CT. Oral premedication (85%, 439 of 518) was preferred for routine inpatients, and rapid IV premedication (89%, 433 of 487) was preferred for urgent ED patients. Of those who provided rapid IV dosing data in the ED, two doses of corticosteroids were used by 53% (216 of 410) and one dose was used by 45% (185 of 410), with academic radiologists more likely than private or hybrid practice radiologists to administer two doses (74% [74 of 100] versus 48% [151 of 312], P < .001, odds ratio, 3.03; 95% confidence interval, 1.84-5.00). Rapid IV premedication was more commonly used in 2020 than in 2009 (60% [433 of 724] versus 29% [20 of 69], P < .001, odds ratio, 3.65; 95% confidence interval, 2.12-6.26). Antihistamine use was common in both inpatient (93%, 480 of 518) and ED settings (92%, 447 of 487). Only 32% (229 of 721) of radiologists practiced in accordance with ACR guidelines, suggesting no need for routine premedication before CE-CT in patients with prior severe hypersensitivity reaction to gadolinium-based contrast media. Nonetheless, most (93%, 670 of 724) said the ACR Manual on Contrast Media was a major determinant of their practice.
Use of rapid IV premedication in urgent settings has increased since 2009, following updated ACR guidelines, but there is disagreement over whether one or two corticosteroid doses is required. Despite reported high reliance on ACR guidelines, deviations from those guidelines remain common. In general, when ACR guidelines were not followed, it was in a risk-averse direction.
确定 2017 年 ACR 更新的指南是否提倡在急诊室 (ED) 患者和报告对碘造影剂过敏的住院患者中使用静脉 (IV) 预用药,以及这是否与临床实践的改变有关。
2020 年 10 月,通过电子邮件向 ACR 的放射科执业医师成员发送了一份匿名调查,询问了两种临床情况是否使用皮质类固醇预用药:有指征的常规 (24 小时内进行) 住院患者增强 CT (CE-CT) 和有指征的紧急 (6 小时内进行) ED CE-CT。在这两种情况下,患者均有中度碘造影剂过敏史。评估了临床管理。将数据与 2009 年的历史对照进行比较。
应答率为 11%(724/6616)。对于住院患者情况,72%(518/724)会使用皮质类固醇预用药进行 CE-CT,28%(200/724)会进行非对比 CT。对于 ED 情况,67%(487/724)会使用皮质类固醇预用药进行 CE-CT,30%(217/724)会进行非对比 CT。对于有指征的住院患者,更倾向于口服预用药(85%,439/518),而对于紧急 ED 患者,则更倾向于快速 IV 预用药(89%,433/487)。在 ED 中提供快速 IV 给药数据的那些人中,53%(410 中的 216)使用了两剂皮质激素,45%(410 中的 185)使用了一剂皮质激素,与私立或混合执业的放射科医生相比,学术放射科医生更有可能使用两剂(74%[100 中的 74]与 48%[312 中的 151],P<.001,优势比,3.03;95%置信区间,1.84-5.00)。与 2009 年相比,2020 年更常使用快速 IV 预用药(60%[724 中的 433]与 29%[69 中的 20],P<.001,优势比,3.65;95%置信区间,2.12-6.26)。在住院患者(93%,480/518)和 ED 环境中(92%,447/487)均普遍使用抗组胺药。只有 32%(721 中的 229)的放射科医生按照 ACR 指南进行实践,表明在有严重对钆类造影剂过敏史的患者中,CE-CT 前无需常规预用药。尽管大多数(93%,670/724)表示 ACR 造影剂手册是他们实践的主要决定因素。
自 2009 年 ACR 更新指南以来,在紧急情况下使用快速 IV 预用药有所增加,但对于需要使用一剂还是两剂皮质激素存在分歧。尽管报告高度依赖 ACR 指南,但仍普遍存在偏离这些指南的情况。一般来说,当不遵循 ACR 指南时,都是以规避风险为导向的。